Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Moderna Jumped 9.7% on Thursday

By Brian Orelli, PhD – Updated Apr 25, 2019 at 8:41PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company's drug cures cancer in mice.

What happened

Shares of Moderna (MRNA -0.58%) jumped 9.7% on Thursday after the company published preclinical data in Science Translational Medicine showing that three mRNAs, which are combined into its mRNA-2752 therapy, can make so-called "cold" tumors immunologically active.

So what

mRNA-2752 contains mRNAs to express IL23 and IL36-gama, a pair of cytokines that cells secrete to stimulate immune cells, as well as OX40L, which sits on the outside of cells and stimulates T cells to attack.

Immuno-oncology checkpoint inhibitors, such as anti-PD-1/PD-L1 antibodies or anti-CTLA-4 antibodies, work well to remove the signals that tumor cells use to block immune cells from attacking. But the drugs don't work for "cold" tumors that lack signals to attract the immune cells in the first place. Essentially, the checkpoint inhibitors are like removing the brake of a car, but some tumors also need a little gas added to get the immune system car headed in the right direction.

In a mouse model of cancer, treatment with the combination of mRNA-2752 and a checkpoint inhibitor resulted in no detectable cancer in a larger fraction of animals compared to the group of animals that got either of the treatments alone.

Woman talking to a doctor in front of a window

Image source: Getty Images.

Now what

Curing mice of cancer is great, but mRNA-2752 will only be able to generate substantial revenue if it can help humans.

Fortunately, investors won't have to wait long to see whether mRNA-2752 works since the drug is already in a phase 1 study testing it in combination with either AstraZeneca's (AZN 0.06%) durvalumab (an anti-PD-L1 antibody) or tremelimumab (an anti-CTLA-4 antibody). The trial is scheduled to be completed next year, but since it's a phase 1 study, Moderna may present interim data, perhaps at the American Society of Clinical Oncology Conference in June.

Check out all our earnings call transcripts.

Brian Orelli and The Motley Fool have no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna Inc. Stock Quote
Moderna Inc.
$175.38 (-0.58%) $-1.02
AstraZeneca PLC Stock Quote
AstraZeneca PLC
$66.21 (0.06%) $0.04

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.